Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 18Lymphoma 12Lymphoma, Non-Hodgkin 11Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, B-Cell, Marginal Zone 5Leukemia, Hairy Cell 4Burkitt Lymphoma 4Recurrence 3Neoplasms 3Lymphoma, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Infections 2Epstein-Barr Virus Infections 2beta-Thalassemia 1Thalassemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphatic Diseases 1Lymphadenopathy 1Leukemia, Prolymphocytic 1

Interventions

venetoclax 5Rituximab 5Cyclophosphamide 4Whole-Body Irradiation 3Magnetic Resonance Spectroscopy 3Cyclosporine 3zanubrutinib 2pirtobrutinib 2fludarabine phosphate 2fludarabine 2Specimen Handling 2Prednisone 2Mycophenolic Acid 2Lenalidomide 2CT-P10 2Biopsy 2treosulfan 1pomalidomide 1obinutuzumab 1ibrutinib 1Vincristine 1Tacrolimus 1Stem Cell Transplantation 1Sirolimus 1R-CHOP protocol 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Methotrexate 1Melphalan 1Maintenance 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × Rituximab × 30 days × Clear all
NCT04840602 2026-06-05

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04542824 2026-06-02

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05100862 2026-05-27

MAHOGANY

BeOne Medicines

Phase 3 Recruiting
780 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡